At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
Prexasertib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
In Brief
A Phase 1 clinical trial evaluating Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, and 1 other intervention for Childhood Solid Neoplasm and 4 related conditions. Completed, enrolled 30 participants across 21 sites.
Detailed Summary
This phase I trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment. Checkpoint kinase 1 inhibitor LY2606368 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChildhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartFeb 2017
Primary CompletionDec 2019
Study CompletionMar 2021
TodayJul 2026
First PostedJun 22, 2016
Enrollment StartFeb 27, 2017
Primary CompletionDec 31, 2019
Study CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.0 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Pharmacokinetic (PK) studyother
Correlative studies
Prexasertibdrug
Given IV